Can diffusion-weighted MR imaging and contrast-enhanced MR imaging precisely evaluate and predict pathological response to neoadjuvant chemotherapy in patients with breast cancer?
Authors:
- 4 April 2012
- journal article
- review article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 135 (1) , 17-28
Abstract
Clinical evidence regarding the value of MRI for therapy responses assessment in breast cancer is increasing. The objective of this study is to compare the diagnostic capability of diffusion-weighted MR imaging (DW-MRI) and contrast-enhanced MR imaging (CE-MRI) to evaluate and predict pathological response in breast cancer patients receiving neoadjuvant chemotherapy (NAC). We performed a meta-analysis of all available studies of the diagnostic performance of DW-MRI or CE-MRI to evaluate and predict pathological response to NAC in patients with breast cancer. We determined sensitivities and specificities across studies, calculated positive and negative likelihood ratios (LR+ and LR−), diagnostic odds ratio (DOR) and constructed summary receiver operating characteristic curves using hierarchical regression models. Methodological quality was assessed by QUADAS tool. Thirty-four studies met the inclusion criteria and involved 1,932 pathologically confirmed patients in total. Methodological quality was relatively high. DW-MRI sensitivity was 0.93 (95 % CI 0.82–0.97) and specificity was 0.82 (95 % CI 0.70–0.90). Overall LR+ was 5.09 (95 % CI 3.09–8.38), LR− was 0.09 (95 % CI 0.04–0.22), and DOR was 55.59 (95 % CI 21.80–141.80). CE-MRI sensitivity was 0.68 (95 % CI 0.57–0.77) and specificity was 0.91 (95 % CI 0.87–0.94). Overall LR+ was 7.48 (95 % CI 5.29–10.57), LR− was 0.36 (95 % CI 0.27–0.48), and DOR was 20.98 (95 % CI 13.24–33.24). Our study confirms that DW-MRI is a high sensitive and CE-MRI is a high specific modality in predicting pathological response to NAC in breast cancer patients. The combined use of DW-MRI and CE-MRI has the potential to improve the diagnostic performance in monitoring NAC. Further large prospective studies are warranted to assess the actual value of this combination in breast cancer preoperative treatment screening.Keywords
This publication has 54 references indexed in Scilit:
- Monitoring neoadjuvant chemotherapy in breast cancer patients: Improved MR assessment at 3 T?Journal of Magnetic Resonance Imaging, 2011
- Diffusion-Weighted Magnetic Resonance Imaging as a Cancer Biomarker: Consensus and RecommendationsNeoplasia, 2009
- Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27Journal of Clinical Oncology, 2008
- Combined Use of Clinical and Pathologic Staging Variables to Define Outcomes for Breast Cancer Patients Treated With Neoadjuvant TherapyJournal of Clinical Oncology, 2008
- Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006Annals of Oncology, 2007
- Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant ChemotherapyJournal of Clinical Oncology, 2007
- Neoadjuvant chemotherapy for operable breast cancerBritish Journal of Surgery, 2007
- Monitoring therapeutic efficacy in breast carcinomasEuropean Radiology, 2006
- Apparent Diffusion Coefficient: a quantitative parameter for in vivo tumor characterizationEuropean Journal of Radiology, 2003
- Diffusion Magnetic Resonance Imaging: an Early Surrogate Marker of Therapeutic Efficacy in Brain TumorsJNCI: Journal of the National Cancer Institute, 2000